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To determine the effects of porcine circovirus type 2 (PCV2) maternal antibodies on and response to
experimental PCV2 infection, 24 piglets were divided into four groups on the basis of the enzyme-linked
immunosorbent assay titers of PCV2 maternal antibodies: group A (n  6; sample/positive [S/P] ratio, <0.2),
group B (n 5; S/P ratio, >0.2 to <0.5), and groups C (n 8) and D (n 5) (S/P ratio, >0.5). Piglets in groups
A, B, and C were inoculated with PCV2 at day 0 and challenged with PCV2 at day 42. Group D piglets were not
exposed to PCV2 at day 0 but were challenged at day 42. Before challenge, seroconversion to PCV2 antibodies
occurred in five of six group A piglets, and the antibody level rose above the cutoff level in one of five group B
piglets. Viremia was detected in five of six, four of five, and two of eight pigs in groups A, B, and C, respectively.
After challenge, PCV2 DNA was detectable from 7 to 21 days postchallenge in the sera from six of six,
four of five, three of eight, and five of five pigs in groups A, B, C, and D, respectively. The results indicated that
protection against PCV2 infection conferred by maternal antibodies is titer dependent: higher titers are
generally protective, but low titers are not.
Porcine circovirus (PCV) was initially isolated as a persistent
contaminant of the porcine kidney PK-15 cell line (25). PCV is
a ubiquitous virus that does not cause any disease in piglets (3,
26). Recently, a new swine disease named postweaning multi-
systemic wasting syndrome (PMWS) (14) was linked to a vari-
ant strain of PCV (1). The PMWS-associated PCV was desig-
nated PCV type 2 (PCV2), whereas the nonpathogenic PK-15
cell-derived PCV was designated PCV1 (2, 7). PCV2, a mem-
ber of the family Circoviridae (27), is a nonenveloped, single-
stranded DNA virus of 1,768 bp (1, 2, 5, 7, 13). The ORF2 gene
of PCV2 encodes the major capsid protein that contains neu-
tralizing epitopes (5, 10, 12, 16), whereas the ORF1 gene
encodes Rep proteins that are involved in virus replication (5,
13). The genetic determinant for PCV2 virulence is not known
(5), although two amino acids in the capsid gene are involved
in PCV2 attenuation (10).
PMWS mainly affects 5- to 16-week-old pigs (2, 14, 23). The
characteristic clinical symptoms of PMWS include progressive
weight loss, dyspnea, enlargement of lymph nodes, diarrhea,
pallor, and jaundice (2, 23). The hallmark microscopic lesions
in PCV2-infected pigs are lymphoid depletion and histiocytic
replacement of lymphoid follicles (2, 23). Piglets coinfected
with PCV2 and porcine parvovirus, PCV2 and porcine repro-
ductive and respiratory syndrome virus, or PCV2 and Myco-
plasma hyopneumoniae had more severe clinical disease and
PCV2-associated lesions than piglets infected with PCV2 (4, 6,
15, 19, 20, 22). A vaccine against PCV2 is not yet available,
although an experimental vaccine based on a chimeric virus of
PCV1 and PCV2 is very promising (8, 9, 11).
Passively acquired antibodies generally confer protection
against viral infections to newborn piglets (21, 24, 28). For
example, maternal antibodies to group A porcine rotavirus
play an important role in reducing the severity of clinical dis-
eases following rotavirus infection, but the level of protection
depended upon the titer of the circulating maternal antibodies
in the newborns (21, 28). Similarly, higher titers of maternal
antibodies to classical swine fever virus (CSFV) inhibited both
cell-mediated and humoral immune responses to a CSFV vac-
cine, but lower titers of maternal antibodies (titer, 64) have
no significant effect on CSFV vaccine (24). Under field condi-
tions, PCV2 infection is widespread and most breeding age
pigs are seropositive, and consequently, the majority of new-
borns have variable levels of PCV2 maternal antibodies (18).
The window of time over which passive antibodies decay is
wide and variable (18). The objective of this study was to assess
the role of PCV2 maternal antibodies in preventing PCV2
infection in piglets.
To select piglets with various levels of PCV2 maternal anti-
bodies for the study, a total of 106 specific-pathogen-free pig-
lets free of M. hyopneumoniae and porcine reproductive and
respiratory syndrome virus were acquired from a commercial
source at 12 days of age. All piglets were tested for the pres-
ence of maternal antibody by a PCV2-specific enzyme-linked
immunosorbent assay (ELISA) prior to grouping (17). Of the
106 piglets tested, 24 piglets were selected for this experiment
solely on the basis of the titers of PCV2 maternal antibodies.
Piglets were separated into four different groups and rooms on
the basis of the titers of maternal antibodies detected 2 days
prior to experimental exposure to PCV2. Six piglets with ma-
ternal antibodies at a sample/positive (S/P) ratio of 0.2 were
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placed in group A, and five piglets with maternal antibodies at
an S/P ratio between 0.2 and 0.5 were placed in group B. Of the
13 pigs with maternal antibodies at an S/P ratio of0.5, 8 were
assigned to group C and 5 to group D (Table 1). The ELISA
S/P ratio cutoff is determined to be 0.2 (17); therefore, piglets
at an S/P ratio 0.2 are considered negative for maternal
antibodies. Piglets with an S/P ratio of 0.2 to 0.5 are con-
sidered to have a low level of detectable maternal antibodies,
whereas piglets with an S/P ratio of 0.5 have a high level of
maternal antibodies (18).
An infectious PCV2 virus stock was generated by transfect-
ing PK-15 cells with a PCV2 infectious DNA clone (8–11), and
the infectivity titer of the PCV2 virus stock was subsequently
determined as previously described (8–11) and used for the
animal experiment. Piglets from groups A, B, and C (Table 1)
were all exposed to PCV2 at day 0: each received 3 ml (1 
103.55 50% tissue culture infective doses) of PCV2 by slow
instillation into the nasal cavity. Piglets in group D were not
exposed to PCV2 at day 0 (Table 1). Piglets in groups A, B, C,
and D were all challenged with 3 ml (1  104.7 50% tissue
culture infective doses) of a homologous PCV2 at 42 days
postinoculation (dpi). To maximize the exposure of pigs to
PCV2 challenge, approximately 1 ml of inoculum was given
intramuscularly, and 2 ml was given intranasally. All piglets
were bled prior to inoculation and weekly thereafter, and nec-
ropsied at 21 days postchallenge (dpc).
Viremia and PCV2 DNA load in sera were determined by a
modified quantitative PCR, and the standardization of the
assay has previously been described (9–11). A standard dilu-
tion series with a known amount of plasmid containing a single
copy of the PCV2 genome was run simultaneously with sam-
ples in each reaction (9, 11). After amplification, a melt curve
analysis was performed to assure the correct product was
formed. Quantification of viral genomic copies per milliliter
(GC/ml) of serum was then carried out essentially as previously
described (10, 11). The sera were also tested for anti-PCV2
antibodies by ELISA as previously described (17). S/P ratios
of PCV2 antibody and PCV2 DNA loads were compared
and evaluated by a simple t test, and analysis of variance and
regression analysis were performed using the TTEST and
GLM procedures of SAS (version 9.1; SAS Institute, Inc.,
Cary, NC).
After exposure to PCV2, seroconversion started at 35 dpi in
four of six piglets in group A. By 42 dpi, five of six piglets had
seroconverted (Fig. 1). The onset of viremia in two of the six
group A piglets occurred at 14 dpi, and they had a viral DNA
load ranging from 105 to 106 GC/ml serum (Table 1). All but
one piglet in group A had viremia by 42 dpi at the time points
TABLE 1. Serum viral DNA loads (genomic copy per ml serum) in pigs throughout the study as detected by quantitative PCR
Groupa or parameter Pig IDb
Serum viral DNA load atc:
0 dpi 7 dpi 14 dpi 21 dpi 28 dpi 35 dpi 42 dpi(0 dpc)
49 dpi
(7 dpc)
56 dpi
(14 dpc)
63 dpi
(21 dpc)
Group A 10    2.6  107 1.4  107 1.2  106 3.2  106 3.4  106 1.2  106 4.7  106
13        2.5  105 1.3  106 2.0  105
36   3.0  106 5.5  108 3.7  108 3.1  107 2.56  108 1.8  109 1.1  107 1.5  107
39    6.3  108 2.4  107 6.2  106  1.4  106 1.2  105 8.7  105
47   1.3  105 5.0  105 1.9  106 5.3  104 1.7  105 2.0  105 3.0  105 2.9  105
53    2.8  108 6.3  106 1.0  109 7.8  105 3.0  105 2.4  107 5.6  104
No. of pigs with viremiad 0/6 0/6 2/6 5/6 5/6 5/6 4/6 6/6 6/6 6/6
Group B 21     1.0  107 3.5  107 2.3  106 5.8  107 3.5  108 6.0  105
26    4.7  106 7.5  104 8.7  104 1.7  106 5.4  105 1.9  105 8.6  104
29    4.6  106 5.8  106 2.5  105 1.3  106 1.4  106 2.2  106 2.6  106
43     3.3  104 5.5  104 8.4  105 9.6  104 3.2  104 1.5  106
71          
No. of pigs with viremia 0/5 0/5 0/5 2/5 4/5 4/5 4/5 4/5 4/5 4/5
Group C 9          
15    1.9  104 2.3  105 5.6  104 3.6  104 3.6  104 9.8  104 
30     2.7  105 1.7  104 3.3  105 3.3  105 3.3  105 7.5  104
34          
50          
54          
61        9.2  105 4.3  105 1.5  105
68          
No. of pigs with viremia 0/8 0/8 0/8 1/8 2/8 2/8 2/8 3/8 3/8 2/8
Group D 4          1.1  106
12        3.9  105 
81         2.5  105 2.1  104
82         7.5  106 3.9  105
106         1.2  105 
No. of pigs with viremia 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 4/5 4/5
a Group A, negative maternal antibody (S/P ratio of 0.2); group B, low maternal antibody (S/P ratio of 0.2 to 0.5); groups C and D, high maternal antibody
(S/P ratio of 0.5).
b Pig ID, pig identification number.
c Serum viral DNA load (number of genomic copies per milliliter of serum) in pigs at the indicated day postinoculation (dpi) or day postchallenge (dpc). , negative
by quantitative PCR.
d Number of pigs with viremia/total number of pigs in the group.
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tested. The low levels of maternal antibodies in group B piglets
waned by 14 dpi. At 21 dpi, the five group B piglets had
become seronegative (S/P ratio, 0.2) and remained so
through 35 dpi. At 42 dpi, one pig in group B (pig 71) sero-
converted and the other four pigs were still seronegative
(Fig. 1). Viremia was first detected in two of five group B pig-
lets at 21 dpi, and by 42 dpi, four piglets had viremia. The high
level of maternal antibodies in group C pigs gradually waned
from 7 to 42 dpi, and there was no rise of antibody titer
between 7 and 42 dpi in any piglets (Fig. 1). Viremia was
detected in one of eight piglets (pig 15) at 21 dpi (Table 1), and
by 42 dpi, only two piglets in group C had viremia, with a viral
DNA load ranging from 104 to 105 GC/ml serum. Statistical
analysis showed that the day of peak viremia in infected piglets
was not related to the initial maternal antibody level (P 
0.50). Peak viremia level decreased with increasing maternal
antibody levels present at 2 dpi (P  0.025). The mean
antibody level at 2 dpi in the piglets that became infected
with PCV2 was lower (S/P ratio, 0.37; standard deviation,
0.328) than in piglets that did not become infected (S/P ratio,
0.84; standard deviation, 0.515) (P  0.044).
These results suggested that the presence of low levels of
PCV2 maternal antibodies does not protect piglets from ex-
perimental PCV2 infection and that high levels of PCV2 ma-
ternal antibodies generally confer protection against PCV2
infection, but not total protection. Statistical analysis showed
that peak viremia levels in piglets were reduced in those piglets
with higher antibody levels at the time of inoculation (P 
0.025). When piglets in group D were challenged at day 42, all
five piglets became infected. These results could explain why
many neonatal piglets born to PCV2-positive sows are still
susceptible to PCV2 infection in swine farms under field con-
ditions.
To determine the length of protection that PCV2 maternal
antibodies can confer to the piglets and to assess the outcome
of prior PCV2 exposure on reinfection of piglets by PCV2, we
challenged all piglets with PCV2 at 42 dpi. At the time of
challenge, five of six pigs in group A were seropositive in re-
sponse to the initial PCV2 exposure at dpi 0 (Fig. 1), and
four of six piglets were viremic at challenge (Table 1). The
maternal antibodies in group B piglets all fell below the S/P
ratio cutoff value by 21 dpi, and all but one piglet were sero-
negative (Fig. 1) and 4 of 5 piglets were viremic at the time of
challenge at 42 dpi (Table 1). In group C, at the time of
challenge at 42 dpi, four piglets were still positive for PCV2
maternal antibodies with S/P ratios ranging from 0.23 to 0.98;
the S/P ratios in the other four pigs were all 0.2 (Fig. 1), and
two piglets were viremic at the time of challenge (Table 1).
After challenge, PCV2 antibody levels in piglets from groups
A and B continued to rise. In contrast, there was no detectable
increase in PCV2 antibody levels in group C piglets after chal-
lenge. After challenge, all six piglets in group A were viremic
FIG. 1. Kinetics of PCV2 antibody in response to infection and PCV2 maternal antibody decay for each group of piglets throughout the
experiment. Piglets in groups A, B, and C were exposed to PCV2 at day 0 (day postinoculation). Piglets in group D were not exposed to PCV2
at day 0 but were challenged with a homologous PCV2 at day 42, along with all piglets in the other groups. The criteria used to assign piglets to
groups on the basis of maternal antibody levels prior to inoculation with PCV2 were as follows: group A, n  6, negative maternal antibody (S/P
ratio, 0.2); group B, n  5, low level of maternal antibodies (S/P ratio, 0.2 to 0.5); groups C (n  8) and D (n  5), high level of maternal
antibodies (S/P ratio, 0.5). Pig identification (ID) numbers are given. The broken lines show an S/P ratio of 0.2.
VOL. 12, 2005 NOTES 1349
and had serum viral DNA loads ranging from 105 to 109 GC/ml
serum at 7 dpc and from 104 to 107 GC/ml serum at 21 dpc. In
group B piglets, four of five piglets remained viremic and had
serum viral DNA loads ranging from 104 to 107 GC/ml serum
at 7 dpc (Table 1). After challenge, two group C piglets re-
mained viremic with no change in the range of serum viral
DNA load, and only one additional piglet, which had a very low
S/P ratio at the time of challenge, developed viremia (Table 1).
Piglet 71 in group B and piglet 54 in group C showed an
increase in antibody titer above the cutoff value after chal-
lenge, even though viremia remained undetectable in the two
pigs (Fig. 1 and Table 1). This could be explained by localized
replication of the virus in lymphoid tissues during the early
phase of replication, thus resulting in an undetectable level of
viremia. Also, piglet 43 in group B had low but persistent
viremia since 28 dpi but was seronegative throughout the
study. The relatively low level of viremia could explain the
absence of a significant increase of antibody in this pig (Table 1).
The group D piglets were not exposed to PCV2 until day 42,
and their maternal antibody level waned gradually over the
course of the experiment (Fig. 1). At the time of challenge, all
five group D pigs still had low levels of maternal antibodies,
with S/P ratios ranging from 0.24 to 0.33. After challenge, there
was no detectable rise of PCV2 antibody titer (Fig. 1), but all
five group D piglets developed viremia at 14 dpc.
These results showed that the PCV2-exposed piglets with no
or low levels of maternal antibodies (groups A and B) were not
protected from the homologous challenge by PCV2, as evi-
denced by continuous viremia despite rising antibody levels. At
the time of challenge, five of six group A piglets had already
developed an active serum PCV2 antibody response from the
initial exposure. Therefore, it is likely that both the humoral
immune response and cell-mediated immune response are re-
quired for full protection (11). Future studies with PCV2 chal-
lenge beyond 42 dpi are needed to fully evaluate the effects of
prior PCV2 exposure on homologous PCV2 challenge.
In conclusion, the results from this study indicated that the
levels of PCV2 maternal antibodies are an important determi-
nant of a piglet’s response to PCV2 infection. It appears that
the higher the levels of maternal antibodies, the more protec-
tion the piglets will have. The data from this study have im-
portant implications for selecting the optimal timing of vacci-
nation, especially with a live PCV2 vaccine when it becomes
available. Since the majority of newborns have PCV2 maternal
antibodies, a live PCV2 vaccine will work most efficiently when
given to piglets older than 7 to 8 weeks of age, at which time
the maternal antibodies have mostly waned.
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